Evaluating SPH7854 Granules in Healthy Individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study aims to assess the safety of SPH7854 granules in healthy subjects. Participants will receive either the investigational drug or a placebo to determine any potential side effects. The study focuses on ensuring that volunteers meet specific health criteria and are fully informed about the trial. By monitoring the health of participants, researchers hope to gather valuable data on the safety profile of SPH7854.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Volunteer to participate in clinical research; Fully understand and know the study and sign the informed consent；
2. Healthy volunteers;
3. Before receiving the investigational drug, the examination results were normal or clinically insignificant;
4. Subjects who have no fertility plan/sperm donation/egg donation plan and voluntarily take effective contraceptive measures, from signing the informed consent to the prescribed time after the last dosing.

Exclusion Criteria:

1. Female subjects who are breastfeeding or have positive pregnancy results;
2. Subjects with chronic, unstable, or recurrent disease or surgery history who are judged by the investigator to be ineligible before signing informed consent;
3. Subjects suffering from allergic diseases or having a history of severe allergies;
4. Subjects who took the drug or food prohibited by the protocol prior to the first dose;
5. Subjects with evidence of infection who could not be enrolled according to the investigator's judgement;
6. Other circumstances that meet the protocol exclusion criteria.

Where it's running

• West China Second University Hospital, Sichuan University
  Chengdu, China Recruiting

Study contacts

• Study coordinator: Qin Yu
• Email: hxeyyb@126.com
• Phone: 0086-028-85501685

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fecal Transplants from Dai vs Han Donors for Ulcerative Colitis

  This study tests whether fecal microbiota transplantation from healthy Dai donors improves symptoms in adults with ulcerative colitis more than transplantation from healthy Han donors.

  Recruiting Phase 2 First Affiliated Hospital of Kunming Medical University · Kunming, Yunnan · NCT07814456

• Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease

  This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619547

• Breast milk mirikizumab levels in lactating people using mirikizumab for IBS/IBD

  This study tests how much mirikizumab passes into breast milk for people who are breastfeeding while on mirikizumab for an approved condition.

  Recruiting at 2 sites Phase 4 Eli Lilly and Company · Glenview, Illinois and 19 other locations · NCT07612267

• Real-world use of guselkumab in Crohn’s disease and ulcerative colitis

  This study tests how long guselkumab stays in the bodies of adults with moderate-to-severe Crohn’s disease or ulcerative colitis treated in real-world clinical settings.

  Recruiting Janssen-Cilag A.G., Switzerland · Bern · NCT07532213

• Gut microbiome and metabolites in people with IBD and depression

  This project will test whether gut microbes and metabolites differ in adults with IBD who have depression compared with those without depression and with healthy adults.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07252427

• Real-world use of guselkumab for adults with moderate-to-severe ulcerative colitis and Crohn's disease in the UK

  This project will see how well guselkumab works for adults with moderate-to-severe ulcerative colitis or Crohn's disease who are starting the treatment in routine UK care.

  Recruiting Janssen-Cilag Ltd. · Harrow · NCT07242248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.